论文部分内容阅读
目的评价奥沙利铂联合卡培他宾化疗方案在治疗晚期胃癌及食管胃结合部腺癌的疗效及安全性。方法选择我院近3年经胃镜活检病理证实的胃癌及食管胃结合部腺癌86例进行临床治疗效果分析,按“实体瘤的疗效评价标准评价客观疗效”。结果 86例患者总治疗周期数344次,中位治疗4个周期,可评价疗效84例,其中初治患者68例,复治患者16例,初治患者有效率36.9%,疾病控制率86.9%;复治患者有效率12.5%,疾病控制率56.1%。中位总生存期11个月,无化疗相关性死亡。常见的Ⅲ-Ⅳ级不良反应为白细胞减少粒26%,粒细胞减少25%,恶心呕吐11.9%,腹泻14.3%,手足综合征10.7%。结论奥沙利铂联合卡培他宾治疗晚期胃癌,减少了住院时间,节省费用,疗效没有降低,值得临床推广应用。
Objective To evaluate the efficacy and safety of oxaliplatin plus capecitabine in the treatment of advanced gastric cancer and esophagogastric junction adenocarcinoma. Methods Totally 86 cases of gastric cancer and esophagogastric junctional adenocarcinoma confirmed by gastroscope biopsy in our hospital in recent 3 years were analyzed for clinical treatment effect and objective therapeutic effect was evaluated according to the criteria of curative effect evaluation of solid tumor. Results The total number of treatment cycles in the 86 patients was 344 and the median treatment time was 4. 84 patients were evaluated, of which 68 patients were newly diagnosed, 16 were retreated, the effective rate was 36.9% and the disease control rate was 86.9% ; Retreatment patients effective rate of 12.5%, disease control rate of 56.1%. The median overall survival was 11 months, with no chemotherapy-related deaths. Common Ⅲ-Ⅳ grade adverse reactions were leukopenia 26%, neutropenia 25%, nausea and vomiting 11.9%, 14.3% of diarrhea, hand-foot syndrome 10.7%. Conclusion Oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer, reducing the length of stay, saving costs, efficacy has not decreased, it is worthy of clinical promotion and application.